Market Overview

UPDATE: Mizuho Securities USA Initiates Coverage On Epizyme Inc On Epigenetics Pure Play


In a report published Friday, Mizuho Securities USA analyst Peter Lawson initiated coverage on Epizyme Inc (NASDAQ: EPZM) with a Buy rating and $35.00 price target.

In the report, Mizuho Securities USA noted, “We are initiating coverage of shares of Epizyme with a Buy rating and a price target of $35. Epizyme is a pure-play on epigenetics, a gene regulatory system that can be exploited to target cancer cells. While the company's pipeline is early phase, valuation is supported by a series of significant biopharmaceutical partners, a series of 4Q14 Phase I readouts, and a platform and IP for further discovery.”

Epizyme closed on Thursday at $28.20.

Latest Ratings for EPZM

Dec 2019UpgradesEqual-WeightOverweight
Jan 2019UpgradesMarket PerformOutperform
Nov 2018MaintainsEqual-WeightEqual-Weight

View More Analyst Ratings for EPZM
View the Latest Analyst Ratings

Posted-In: Mizuho Securities USA Peter LawsonAnalyst Color Initiation Analyst Ratings


Related Articles (EPZM)

View Comments and Join the Discussion!

Latest Ratings

VIACJP MorganReinstates50.0
NUVASVB LeerinkMaintains92.0
SRPTCantor FitzgeraldMaintains211.0
LULUGoldman SachsMaintains219.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Morning Market Losers

Citigroup Offers Up A Pair Trade For AllianceBernstein Holding LP And Artisan Partners Asset Management Inc